MicroRNAs (miRNAs) attenuate gene expression by pairing with the 3 0 UTR of target transcripts inducing RNA cleavage or translational inhibition. These small regulatory molecules are central to various physiologic processes and their disruption is associated with human diseases, particularly cancer. 1 MiRNAs map predominantly to fragile sites in the genome, and gain or loss of chromosomal material may result in a miRNA deregulation. 2 In hematological malignancies, amplification of chromosome 13q31 in B-cell lymphomas leads to overexpression of the miRNA cluster 17-92 3 and deletion of chromosome 13q14 in chronic lymphoid leukemia has been linked to downregulation of miR-15a and miR16-1. In chronic myeloid leukemia (CML), deletion of the derivative chromosome 9 -der(9q) -is found in 10-15% of the patients and has been associated with poor prognosis. 6, 7 More recently, genetic heterogeneity among these cases was noted and it appears that only large centromeric deletions (B30% of deleted cases) and/or those spanning the ABL-BCR junction are associated with an adverse prognosis. 6, 7 These data are particularly relevant because two miRNAs, miR219-2 and miR-199b, map approximately 2.4 Mb centrometic to the ABL1 locus (Figure 1a ) and may be lost in CML cases with large der(9q) deletions.
To define the potential involvement of these miRNAs in the pathogenesis of CML with der(9q) deletion, we identified a collection of 48 t(9;22)-positive CML cases and used fluorescence in situ hybridization to ascertain their der(9q) status. Five CML cell lines, which either lacked ABL-BCR expression (K562, CMLT1, SD1 and TK6) or is known to have a der(9q) deletion (MC3) 9 were also studied. All cases were investigated with the BCR-ABL dual-color/dual-fusion probe system (Abbott Molecular, IL, USA) as well as with three bacterial artificial chromosome (BAC) clones (RP11-395P17, RP11-339B21 and RP11-409K20FBACPAC Resources Center, Oakland, CA, USA) mapping centromeric to the ABL locus. Importantly, two of these probes specifically included miR-219-2 or miR-199b sequences ( Figure 1a ). BAC DNAs were isolated and hybridized to the patient's slides as we described previously. 10 Using this strategy, we found der(9q) deletion in 7 (14.5%) of the 48 CML patients analyzed. In two samples, the deletion extended as far centromeric as to include both miRNA loci ( Figure 1b) ; there were no instances of deletion of miR-219-2 or 199b in samples with an otherwise intact der(9q). We confirmed the der(9q) deletion in MC3 but the miRNA loci were preserved in this cell line. All the other cell lines showed multiple copies of normal chromosome 9 and der(9) and the status of the miRNA loci could not be ascertained (data not shown). Thus, these data confirmed the idea that these miRNAs could be targeted in CML cases that harbor large der(9q) deletion.
To integrate genomic and expression data, we used a quantitative TaqMan stem-loop real-time reverse transcription-PCR (RT-PCR) approach (Applied Biosystems, Foster City, CA, USA). In these assays, we specifically measured the expression of the mature isoforms of miRNA-219-2 and 199b in the patients with large (encompassing the miRNAs, n ¼ 2) or small (sparing the miRNAs n ¼ 4) der(9q) deletions. Importantly, for these experiments RNA was isolated from the same samples used to perform fluorescence in situ hybridization and the expression of the small nucleolar RNA U18 was used as house-keeping control sequence. Furthermore, except for the size of the der(9q) deletions, the hematological and cytogenetic features of these patients were mostly comparable (Table 1) . Therefore, despite this limited sample size, we were confident that the data obtained with these assays would be informative. Expression of miR-199b was consistently higher than that of miR-219 (Po0.001, t-test). However, for both miRNAs these levels were indistinguishable in samples with one or two gene copies (P ¼ 0.85, miR-199b; P ¼ 0.74 miR-219-2) (Figure 1c) . Interestingly, the levels of miR-199b varied significantly among the six patients analyzed indicating that dynamic regulation of this gene is ongoing in BCR-ABL positive cells. Conversely, perhaps owing to its very low levels, miRNA 219-2 expression was more uniform within this sample collection suggesting that this miRNA may not play a physiologic role in cells of the hematopoietic lineage.
In summary, our data suggest that although miR-219-2 and 199b can be hemizygously lost in a significant proportion of CML cases with der(9q) deletion, they are unlikely to play a dominant role in this disease pathogenesis. Analyses of an expanded sample set of patients with large der(9q) deletion should be useful in confirming these results. Furthermore, our findings are in agreement with recent reports pointing to a lack of correlation The expression values for these miRNAs were normalized by that of the snoRNA U18. The results are reported as relative expression determined by the DDCT formula, as described; 8 shown is a representative assay of three independent biological repeats performed in duplicate. BAC, bacterial artificial chromosome; CML, chronic myeloid leukemia; miRNAs, microRNAs; RT-PCR, reverse transcription-PCR; snoRNA, small nucleolar RNA.
Letters to the Editor between hemizygous loss of chromosome material and downregulation of targeted miRNAs. 5 The pathogenically relevant target gene(s) at der(9q) remains to be identified. Chromosomal translocation t(8;21)(q22;q22) occurs in about 10% of all cases of acute myeloid leukaemia (AML) and is one of the most frequent chromosomal abnormalities found in AML. 1 This translocation generates the RUNX1/RUNX1T1 (AML1/ MTG8, AML1/ETO) fusion gene, which by itself is not sufficient for full leukaemic transformation, but which supports human haematopoietic stem/progenitor cell self-renewal in vivo as well as leukaemic proliferation and clonogenicity ex vivo.
Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo
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Generation of RUNX1/RUNX1T1 may not only be an initiating event in leukaemogenesis, but might also become a leukaemiaspecific target for therapeutic approaches. However, its role in leukaemic persistence in vivo and, in particular, its significance for leukaemic stem cells has not been established yet.
One prerequisite for studying possible functions of RUNX1/ RUNX1T1 in maintaining leukaemia in vivo and the development of therapies targeting this genetic lesion is the availability of suitable animal model systems. Several transgenic and knockin mouse models have been developed to study RUNX1/ RUNX1T1-driven leukaemogenesis in murine haematopoietic cells. 5 However, in vivo studies of RUNX1/RUNX1T1 in the human leukaemic background are currently limited due to a lack of suitable xenotransplantation models, as t(8;21)-positive leukaemic cells including the established cell lines do not or only rarely engraft in Nod/Scid mouse strains. 6 The Rag2 þ , CD34 þ and CD33 þ cells, which is concordant with the immunophenotype of Kasumi-1 cells (Figures 1b and c and data not shown) . Notably, such extramedullary myeloid tumours (granulocytic sarcomas and chloromas) are found in some 20% of all t(8;21) AML cases. 8 In less than half of the animals, we observed infiltration of the spleen by leukaemic cells, but neither bone marrow nor liver infiltration (Figure 1c) . Consistent with this, RUNX1/RUNX1T1 protein was strongly expressed in tumours, occasionally and weakly in spleen and never in liver (Figure 1d) .
We recently analysed the significance of RUNX1/RUNX1T1 for leukaemic proliferation and clonogenicity using short interfering RNAs (siRNAs). A single siRNA treatment caused a transient reduction in fusion protein levels lasting 5-7 days. siRNA-mediated RUNX1/RUNX1T1 depletion restored myeloid differentiation capacity, inhibited proliferation and severely impaired leukaemic clonogenicity in vitro.
3,4 However, these
